Medicine Recommendations

Severe pain and breathlessness in patients with symptoms due to a palliative (life limiting) illness

Complex pain syndrome

MHRA Drug Safety Alert - Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men

MHRA Drug Safety Alert - Mycophenolate mofetil: pure red cell aplasia

MHRA Drug Safety Alert - Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis

Alcohol dependence (NICE TA325)

NICE TA325  Nalmefene for reducing alcohol consumption in people with alcohol dependence

Managing overweight and obesity (NICE TA494)

NICE TA494 - Naltrexone–bupropion for managing overweight and obesity

Pain: Anti-inflammatory

Treatment of pain

Pain.

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Depressive illness

Chronic Neuropathic Pain

Treatment and prophylaxis of schizophrenia

Tablets, orodispersible tablets, powder for solution for injection

Nausea and vomiting, appetite stimulant.

Schizophrenia

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Rapid tranquilization

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Parkinson’s disease – adjunctive therapy in adults with end-of-dose motor fluctuations who cannot be stabilised on preparations of levodopa/DOPA decarboxylase inhibitors

Anxiety (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Treatment of epilepsy

MHRA Drug Safety Update - Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products

Pain

Restless Legs Syndrome

Chronic pain